Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.37 |
| ▸ | MEN1 | O00255 | 5/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25955922 | 0.83 | PSD (0.46) | MAPTALDH1A1LMNANPSR1MAPK1 | |
| SCHEMBL22347691 | 0.77 | KDM4E (0.49) | MAPTALDH1A1MAPK1KMT2AMEN1 | |
| SCHEMBL25956091 | 0.77 | MAP3K12 (0.35) | MAP3K12PDE10A | |
| SCHEMBL25956090 | 0.76 | MAP3K12 (0.35) | MAP3K12PDE10A | |
| SCHEMBL25956087 | 0.75 | PDE10A (0.38) | MAP3K12PDE10A | |
| SCHEMBL3156019 | 0.73 | MAPT (0.52) | MAPTALDH1A1LMNAALOX12NPSR1 | |
| SCHEMBL25324098 | 0.72 | PDK1 (0.38) | MAP3K12PDE10A | |
| SCHEMBL1667915 | 0.72 | CRACR2A (0.49) | MAPTALDH1A1LMNAALOX12NPSR1 | |
| SCHEMBL25339487 | 0.71 | MAPT (0.45) | MAPTALDH1A1LMNANPSR1POLB | |
| SCHEMBL3387040 | 0.71 | MAPT (0.49) | MAPTALDH1A1LMNAALOX12NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136559-A1 | SMO MODULATOR COMPOUNDS | Omass Therapeutics Limited (GB) | 2025-05-01 | — | — | US | disclosed |
| EP-4472959-A1 | SMO MODULATOR COMPOUNDS | Omass Therapeutics Limited (GB) | 2024-12-11 | — | — | EP | disclosed |
| WO-2023148481-A1 | SMO MODULATOR COMPOUNDS | Omass Therapeutics Limited (GB) | 2023-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136559-A1 | SMO MODULATOR COMPOUNDS | SMO, SHH, GLI1 | MAPT 4299/4885ALDH1A1 2617/4885LMNA 4433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.